Tempus AI Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 3,800

Employees

  • Stock Symbol
  • TEM

Stock Symbol

  • Investments
  • 13

  • Share Price
  • $59.61
  • (As of Thursday Closing)

Tempus AI General Information

Description

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Contact Information

Website
www.tempus.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 600 West Chicago Avenue
  • Suite 510
  • Chicago, IL 60654
  • United States
+1 (800)
Primary Industry
Decision/Risk Analysis
Stock Exchange
NAS
Corporate Office
  • 600 West Chicago Avenue
  • Suite 510
  • Chicago, IL 60654
  • United States
+1 (800)

Tempus AI Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tempus AI Stock Performance

As of 19-Nov-2026, Tempus AI’s stock price is $59.61. Its current market cap is $10.9B with 182M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$59.61 $63.62 $40.77 - $89.09 $10.9B 182M 6.93M -$1.06

Tempus AI Financials Summary

As of 30-Sep-2026, Tempus AI has a trailing 12-month revenue of $1.51B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 15,497,626 11,081,607 5,320,588
Revenue 1,509,350 1,271,789 693,398 531,822
EBITDA (48,496) (131,135) (621,490) (140,929)
Net Income (189,294) (245,028) (705,809) (214,118)
Total Assets 2,451,598 2,274,838 926,116 564,052
Total Debt 1,431,911 1,327,130 468,094 488,142
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tempus AI Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tempus AI‘s full profile, request access.

Request a free trial

Tempus AI Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Tempus AI‘s full profile, request access.

Request a free trial

Tempus AI Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to f
Decision/Risk Analysis
Chicago, IL
3,800 As of 2025

Mountain View, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tempus AI Competitors (26)

One of Tempus AI’s 26 competitors is HeartFlow, a Formerly VC-backed company based in Mountain View, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
HeartFlow Formerly VC-backed Mountain View, CA
GenoSpace Corporate Backed or Acquired Boston, MA
NantHealth Formerly VC-backed Lewisville, TX
PierianDx Private Equity-Backed Creve Coeur, MO
Ibex Medical Analytics Venture Capital-Backed Tel Aviv, Israel
You’re viewing 5 of 26 competitors. Get the full list »

Tempus AI Patents

Tempus AI Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260354802-A1 Detecting low ejection fraction from electrocardiogram data using artificial intelligence Pending 20-Jul-2026
WO-2026232011-A1 Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing Pending 30-Apr-2025
US-20260337665-A1 Methylation conversion assessment and controls Pending 16-Apr-2025
EP-4797268-A1 Systems and methods for characterizing mutations Pending 25-Feb-2025
US-20260253673-A1 Systems and methods for characterizing mutations Pending 25-Feb-2025 G16B30/10
To view Tempus AI’s complete patent history, request access »

Tempus AI Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tempus AI Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tempus AI‘s full profile, request access.

Request a free trial

Tempus AI Investments & Acquisitions (13)

Tempus AI’s most recent deal was a Merger/Acquisition with Personalis for . The deal was made on 20-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Personalis 20-Jul-2026 Merger/Acquisition Drug Discovery
OneOme (A Portfolio of Pharmacogenetics Assets) 24-Nov-2025 Corporate Asset Purchase Buildings and Property
Paige 22-Aug-2025 Merger/Acquisition Decision/Risk Analysis
Deep 6 AI 11-Mar-2025 Merger/Acquisition Other Healthcare Technology Systems
Asylia Diagnostics 18-Feb-2025 Later Stage VC Discovery Tools (Healthcare)
You’re viewing 5 of 13 investments and acquisitions. Get the full list »

Tempus AI ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Tempus AI’s complete esg history, request access »

Tempus AI Affiliates

Subsidiaries (4)

Name Industry Location Year Founded
Paige New York, NY 2017
Deep 6 AI Pasadena, CA 2016
SEngine Precision Medicine Bothell, WA 2015
Ambry Genetics Aliso Viejo, CA 1999

Tempus AI FAQs

  • When was Tempus AI founded?

    Tempus AI was founded in 2015.

  • Where is Tempus AI headquartered?

    Tempus AI is headquartered in Chicago, IL.

  • What is the size of Tempus AI?

    Tempus AI has 3,800 total employees.

  • What industry is Tempus AI in?

    Tempus AI’s primary industry is Decision/Risk Analysis.

  • Is Tempus AI a private or public company?

    Tempus AI is a Public company.

  • What is Tempus AI’s stock symbol?

    The ticker symbol for Tempus AI is TEM.

  • What is the current stock price of Tempus AI?

    As of 19-Nov-2026 the stock price of Tempus AI is $59.61.

  • What is the current market cap of Tempus AI?

    The current market capitalization of Tempus AI is $10.9B.

  • What is Tempus AI’s current revenue?

    The trailing twelve month revenue for Tempus AI is $1.51B.

  • Who are Tempus AI’s competitors?

    HeartFlow, GenoSpace, NantHealth, PierianDx, and Ibex Medical Analytics are some of the 26 competitors of Tempus AI.

  • What is Tempus AI’s annual earnings per share (EPS)?

    Tempus AI’s EPS for 12 months was -$1.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process